Doctors at Evelina Children's Hospital in London have invented one of Europe's top-selling medical iPhone applications, with more than 100 downloads every week. The Paediatric Emergency Drugs app enables medical and nursing staff to quickly work out complicated drug calculations during emergencies to ensure paediatric patients receive the correct drug doses for their age and weight. Paediatric intensive care consultant, Dr Shelley Riphagen, came up with the idea with the help of Dr Andrew Durward's IT skills and the app went on sale in March this year. Dr Riphagen said: "When critically-ill children present to district general hospitals with emergencies, the right doses of drugs according to the child's age and weight need to be available immediately. The Paediatric Emergency Drugs app allows this to happen. It has made a huge difference to the care of our patients and it's really fantastic to know that it's also appreciated by medical and nursing staff in hospitals across Europe." The project was made possible through collaboration with UBQO.
Medical app is best seller
You may also like
Manufacturing
Anxine responds to rising demand for integrated turnkey packaging solutions
Read moreAnxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Pharmaceutical
MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients
The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing
As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Regulatory
Oncopeptides to seek EMA label expansion for Pepaxti to include third-line multiple myeloma treatment
The company has said it will submit a Type II variation to the EMA to expand Pepaxti's indication to include patients with multiple myeloma who have received at least two prior lines of therapy — a move that would double the addressable patient population and treatment cycle potential in Europe
Pharmaceutical
Ardena strengthens executive team to drive its next phase of growth
Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally